Innate Immune Responses and CS Repeat-Specific Neutralizing Antibodies Following Vaccination by Skin Scarification

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Jun 23

PMID 35734173

Authors

Robert A Mitchell

Rita Altszuler

Sandra Gonzalez

Roshawn Johnson

Ute Frevert

Elizabeth Nardin

Affiliations

Soon will be listed here.

Abstract

The skin is the site of host invasion by the mosquito-borne parasite, which caused an estimated 229 million infections and 409,000 deaths in 2019 according to WHO World Malaria report 2020. In our previous studies, we have shown that skin scarification (SS) with a circumsporozoite (CS) peptide in the oil-in-water adjuvant AddaVax containing a combination of TLR 7/8 and TLR 9 agonists can elicit sporozoite neutralizing antibodies. SS with AddaVax + TLR agonists, but not AddaVax alone, elicited CD4+ Th1 cells and IgG2a/c anti-repeat antibody. To explore the innate immune responses that may contribute to development of adaptive immunity following SS, we examined the skin at 4h and 24h post priming with CS peptide in AddaVax with or without TLR agonists. H&E stained and IHC-labeled dorsal skin sections obtained 24h post SS demonstrated a marked difference in the pattern of infiltration with F4/80+, CD11b+ and Ly6G+ cells at the immunization site, with the lowest intensity noted following SS with AddaVax + TLR agonists. Serum collected at 4h post SS, had reproducible increases in IL-6, MIP-3α, IL-22 and IP-10 (CXCL10) following SS with AddaVax + TLR agonists, but not with AddaVax alone. To begin to decipher the complex roles of these pro-inflammatory cytokines/chemokines, we utilized IP-10 deficient (IP-10 -/-) mice to examine the role of this chemokine in the development of anti-repeat antibody response following SS. In the absence of IP-10, the levels of Th1-type IgG2a/c antibody and kinetics of the primary anti-repeat antibody response were reduced following prime and boost. The IP-10 chemokine, present as early as 4h post prime, may provide an early serological marker for rapid screening of adjuvant formulations and delivery platforms to optimize SS-induced humoral immunity to CS repeats as well as other pathogens.

Citing Articles

Immunopeptides: immunomodulatory strategies and prospects for ocular immunity applications.

Tang Y, Qu S, Ning Z, Wu H Front Immunol. 2024; 15:1406762.

PMID: 39076973 PMC: 11284077. DOI: 10.3389/fimmu.2024.1406762.

References

Regules J, Cicatelli S, Bennett J, Paolino K, Twomey P, Moon J . Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. J Infect Dis. 2016; 214(5):762-71. DOI: 10.1093/infdis/jiw237. View

Li Z, Gothard E, Coles M, Ambler C . Quantitative Methods for Measuring Repair Rates and Innate-Immune Cell Responses in Wounded Mouse Skin. Front Immunol. 2018; 9:347. PMC: 5835106. DOI: 10.3389/fimmu.2018.00347. View

Nardin E, Oliveira G, Castro Z, Nussenzweig R, Schmeckpeper B, Hall B . Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J Infect Dis. 2000; 182(5):1486-96. DOI: 10.1086/315871. View

De Oliveira G, Clavijo P, Nussenzweig R, Nardin E . Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application. Vaccine. 1994; 12(11):1012-7. DOI: 10.1016/0264-410x(94)90337-9. View

Wang J, Shah D, Chen X, Anderson R, Wu M . A micro-sterile inflammation array as an adjuvant for influenza vaccines. Nat Commun. 2014; 5:4447. PMC: 4391636. DOI: 10.1038/ncomms5447. View

Tomai M, Vasilakos J . TLR-7 and -8 agonists as vaccine adjuvants. Expert Rev Vaccines. 2011; 10(4):405-7. DOI: 10.1586/erv.11.26. View

Groom J, Luster A . CXCR3 in T cell function. Exp Cell Res. 2011; 317(5):620-31. PMC: 3065205. DOI: 10.1016/j.yexcr.2010.12.017. View

Schmidt L . Plasmodium cynomolgi infections in the rhesus monkey. Am J Trop Med Hyg. 1982; 31(3 Pt 2):609-611. DOI: 10.4269/ajtmh.1982.31.609. View

Yoshida N, Nussenzweig R, Potocnjak P, NUSSENZWEIG V, Aikawa M . Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science. 1980; 207(4426):71-3. DOI: 10.1126/science.6985745. View

10.

OHagan D . MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007; 6(5):699-710. DOI: 10.1586/14760584.6.5.699. View

11.

Hoffman S, Goh L, Luke T, Schneider I, Le T, Doolan D . Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002; 185(8):1155-64. DOI: 10.1086/339409. View

12.

Vanderberg J, Frevert U . Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol. 2004; 34(9):991-6. DOI: 10.1016/j.ijpara.2004.05.005. View

13.

NUSSENZWEIG V, Nussenzweig R . Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol. 1989; 45:283-334. DOI: 10.1016/s0065-2776(08)60695-1. View

14.

Klinman D . Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol. 2006; 25(3-4):135-54. DOI: 10.1080/08830180600743057. View

15.

Moody M, Santra S, Vandergrift N, Sutherland L, Gurley T, Drinker M . Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J Virol. 2014; 88(6):3329-39. PMC: 3957956. DOI: 10.1128/JVI.03309-13. View

16.

Krathwohl M, Anderson J . Chemokine CXCL10 (IP-10) is sufficient to trigger an immune response to injected antigens in a mouse model. Vaccine. 2006; 24(15):2987-93. DOI: 10.1016/j.vaccine.2005.11.032. View

17.

Foquet L, Hermsen C, van Gemert G, Van Braeckel E, Weening K, Sauerwein R . Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J Clin Invest. 2013; 124(1):140-4. PMC: 3871238. DOI: 10.1172/JCI70349. View

18.

Tomai M, Miller R, Lipson K, Kieper W, E Zarraga I, Vasilakos J . Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines. 2007; 6(5):835-47. DOI: 10.1586/14760584.6.5.835. View

19.

Nussenzweig R, Vanderberg J, MOST H, Orton C . Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature. 1967; 216(5111):160-2. DOI: 10.1038/216160a0. View

20.

White M, Verity R, Griffin J, Asante K, Owusu-Agyei S, Greenwood B . Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015; 15(12):1450-8. PMC: 4655306. DOI: 10.1016/S1473-3099(15)00239-X. View